GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (AMEX:PTN) » Definitions » EBIT

Palatin Technologies (Palatin Technologies) EBIT : $-31.58 Mil (TTM As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Palatin Technologies EBIT?

Palatin Technologies's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-7.84 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-31.58 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Palatin Technologies's annualized ROC % for the quarter that ended in Dec. 2023 was -486.69%. Palatin Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2,379.07%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Palatin Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -156.26%.


Palatin Technologies EBIT Historical Data

The historical data trend for Palatin Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies EBIT Chart

Palatin Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.19 -22.41 -33.57 -36.17 -32.20

Palatin Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.96 -7.14 -10.71 -5.88 -7.84

Competitive Comparison of Palatin Technologies's EBIT

For the Biotechnology subindustry, Palatin Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palatin Technologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palatin Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Palatin Technologies's EV-to-EBIT falls into.



Palatin Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Palatin Technologies  (AMEX:PTN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Palatin Technologies's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-26.6 * ( 1 - 0% )/( (5.63 + 5.301)/ 2 )
=-26.6/5.4655
=-486.69 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Palatin Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-31.368/( ( (1.385 + max(-8.895, 0)) + (1.252 + max(-7.975, 0)) )/ 2 )
=-31.368/( ( 1.385 + 1.252 )/ 2 )
=-31.368/1.3185
=-2,379.07 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.349 + 1.598 + 1.333) - (9.422 + 0 + 3.753)
=-8.895

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.346 + 0 + 0.414) - (7.208 + 0 + 3.527)
=-7.975

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Palatin Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-31.577/20.208
=-156.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Palatin Technologies EBIT Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Palatin Technologies (Palatin Technologies) Business Description

Traded in Other Exchanges
Address
4B Cedar Brook Drive, Cranbury, NJ, USA, 08512
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
Executives
Stephen T Wills officer: Executive Vice President, CFO PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Alan W Dunton director VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Carl Spana director, officer: President and CEO PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Deveer Robert K Jr director C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Joseph Stanley Hull director PALATIN TECHNOLOGIES INCORPORATED, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arlene Morris director C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Anthony M. Manning director C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Angela Rossetti director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Robert I Taber director C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Zola P Horovitz director C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Perry B Molinoff director, officer: Exec. VP Research and Devel. C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104